The agreement states Amgen will co-develop, manufacture and manage the approval application process for four of its biosimilars for the Chinese market.
Nanjing, Jiangsu, China-headquartered Simcere will distribute and commercialise approved candidates.
Amgen spokesperson Kelley Davenport told us “The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology. At this time, we are not sharing additional details.”
Simcere’s president Honggang Feng said the partnership allows the companies access to inflammation and oncology markets in China.
“This strategic partnership between a world-renowned biotechnology company and leading Chinese pharma will help to accelerate development and launch of United States and European approved biosimilars in China,” he added.
Financial terms of the agreement were not disclosed.
Amgen in Asia
Amgen said it sees an increased demand for biosimilars across the Asia-Pacific.
“This agreement furthers Amgen’s efforts to reach more patients in Asia by bringing high quality biosimilars medicines to patients suffering from debilitating and potentially life-threatening conditions,” said Asia-Pacific Region general manager, Penny Wan.
Davenport told us the firm sees opportunities in Japan, and is monitoring government incentives in this biosimilar domain.
“In recent years different Japanese government incentives have been put into place to encourage the use of generics and has resulted in significant uptake over the last couple of years, and we are hopeful that the Japanese government and other countries will similarly provide incentives to use biosimilars,” she said.